KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cash & Equivalents (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Cash & Equivalents data on record, last reported at $282.0 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 3484.51% year-over-year to $282.0 million; the TTM value through Dec 2025 reached $282.0 million, up 3484.51%, while the annual FY2025 figure was $282.0 million, 3484.51% up from the prior year.
  • Cash & Equivalents reached $282.0 million in Q4 2025 per AMRX's latest filing, up from $34.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $452.1 million in Q1 2021 and bottomed at $5.9 million in Q2 2024.
  • Average Cash & Equivalents over 5 years is $103.7 million, with a median of $72.8 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 12972.15% in 2021, then crashed 97.77% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $8.9 million in 2021, then rose by 3.37% to $9.3 million in 2022, then soared by 889.54% to $91.5 million in 2023, then plummeted by 91.41% to $7.9 million in 2024, then soared by 3484.51% to $282.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $282.0 million in Q4 2025, $34.7 million in Q3 2025, and $71.5 million in Q2 2025.